A phase I/II study has reported positive results for a gene therapy aimed at treating Huntington's disease, with some outlets suggesting the treatment may slow disease progression. However, regulatory hurdles have emerged, with the FDA reportedly requiring additional study or citing insufficient data for submission. The status of the therapy's development is uncertain, with some sources indicating a potential halt in plans and others discussing future possibilities for treatment.